JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
After market 22:02:20 | |||
| 149.9 USD | +0.04% |
|
150 | +0.04% |
| 05-09 | J&J: technological update in cardiac arrhythmia | CF |
| 05-07 | Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs | RE |
| Sales 2024 * | 88.37B 7,052B | Sales 2025 * | 90.78B 7,244B | Capitalization | 361B 28,779B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B 1,759B | Net income 2025 * | 23.09B 1,843B | EV / Sales 2024 * | 4 x |
| Net cash position 2024 * | 7B 558B | Net cash position 2025 * | 21.07B 1,682B | EV / Sales 2025 * | 3.74 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
15.7
x | Employees | 131,900 |
| Yield 2024 * |
3.22% | Yield 2025 * |
3.36% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
| 1 day | -0.12% | ||
| 1 week | -0.05% | ||
| Current month | +3.64% | ||
| 1 month | -1.60% | ||
| 3 months | -4.41% | ||
| 6 months | +1.65% | ||
| Current year | -4.40% |
1 week
147.91
150.10
1 month
143.13152.33
Current year
143.13163.58
1 year
143.13175.97
3 years
143.13186.69
5 years
109.16186.69
10 years
81.79186.69
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 31/12/97 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 04/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 24/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 18/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 21/10/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.01% | 0 M€ | +11.39% | - | |
| 12.91% | 0 M€ | +7.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 149.9 | +0.04% | 5 537 301 |
| 09/05/24 | 149.8 | +0.60% | 6,546,153 |
| 08/05/24 | 149 | +0.15% | 7,735,148 |
| 07/05/24 | 148.7 | +0.09% | 7,333,730 |
| 06/05/24 | 148.6 | -0.46% | 5,042,757 |
Delayed Quote Nyse, May 09, 2024 at 09:00 pm
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.8
USD
Average target price
173.3
USD
Spread / Average Target
+15.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.40% | 361B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +17.02% | 239B | |
| +8.05% | 204B | |
| -7.40% | 198B | |
| +8.62% | 168B | |
| +4.59% | 125B |
- Stock Market
- Equities
- JNJ Stock
